News

IXEMPRA is indicated as monotherapy or in combination with capecitabine for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory

Under this Agreement, the Company will manufacture and supply Alferon N Injection to physicians and patients through Armada’s national network of specialty pharmacies. Armada has agreed to provide

With the increase, NRC-IRAP’s total non-refundable financial contributions to DelMar total CDN$420,000 to date. "We are very pleased with the continued support to accelerate and expand our non-clinical

The complaint, filed by the U.S. Department of Justice, sought a permanent injunction against the company and its owners for unlawfully manufacturing and distributing unapproved new drugs, misbranded

Strensiq is the first approved treatment for HPP, an ultra-rare, genetic, metabolic disease in which patients experience devastating, progressive effects on multiple organs of the body, leading to

The NMDA receptor helps in the transfer of electrical signals between neurons in the brain and in the spinal column. Initial results from the company’s completed single ascending

It was recently approved by the U.S. Food and Drug Administration (FDA) for the once-daily, topical treatment of acne vulgaris. Epiduo Forte Gel offers patients and physicians a

Participants in the Phase 3, open-label extension study, B-YOND, maintained low bleeding rates with one to two week prophylaxis regimens, according to data from an interim analysis. Investigators

Xilonix, a novel anti-cancer agent, is being developed via a ground-breaking regulatory path that XBiotech established in collaboration with the scientific advisory committee of the European Medicines Agency